<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001876</url>
  </required_header>
  <id_info>
    <org_study_id>990056</org_study_id>
    <secondary_id>99-HG-0056</secondary_id>
    <nct_id>NCT00001876</nct_id>
  </id_info>
  <brief_title>Lung Disease Associated With Rheumatoid Arthritis</brief_title>
  <official_title>Pulmonary Fibrosis Associated With Rheumatoid Arthritis: Definition of the Natural History of Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Human Genome Research Institute (NHGRI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Pulmonary fibrosis (PF) is a condition in which the lungs of a patient become scarred and&#xD;
      fibrous. It has been known to occur in as many as 40% of patients diagnosed with rheumatoid&#xD;
      arthritis (RA). The cause of the pulmonary fibrosis in patients with RA is unknown.&#xD;
&#xD;
      Patients participating in this study will undergo a series of tests and examinations before&#xD;
      and throughout the study. The tests include blood and urine tests, electrical measures of&#xD;
      heart function (ECG), chest x-rays, CAT scans, nuclear medicine scans, breathing tests,&#xD;
      exercise tests, and fiberoptic bronchoscopy.&#xD;
&#xD;
      The goals of this study are to:&#xD;
&#xD;
        1. Estimate how common pulmonary fibrosis is in patients with rheumatoid arthritis,&#xD;
&#xD;
        2. Describe the natural course of pulmonary fibrosis in patients with rheumatoid arthritis,&#xD;
&#xD;
        3. Estimate the survival rate of patients with pulmonary fibrosis and rheumatoid arthritis,&#xD;
           and&#xD;
&#xD;
        4. Learn more about the factors that contribute to the development or progression fibrotic&#xD;
           lung disease....&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary fibrosis is an extra-articular manifestation of rheumatoid arthritis whose etiology&#xD;
      remains uncertain. Although the clinical course of many individuals with this disorder can&#xD;
      mimic that observed in patients with idiopathic pulmonary fibrosis, the natural history of&#xD;
      fibrotic lung disease associated with rheumatoid arthritis remains largely undefined. It is&#xD;
      the intent of this clinical protocol to (1) estimate the prevalence of pulmonary fibrosis in&#xD;
      individuals with rheumatoid arthritis, (2) define the natural history of pulmonary fibrosis&#xD;
      in patients with rheumatoid arthritis, (3) estimate the survival rate of individuals with&#xD;
      pulmonary fibrosis and rheumatoid arthritis, and (4) examine pulmonary physiologic,&#xD;
      radiologic, and biochemical markers that predict the development or progression of fibrotic&#xD;
      lung disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 5, 1999</start_date>
  <completion_date type="Actual">December 11, 2007</completion_date>
  <primary_completion_date type="Actual">November 9, 2005</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence</measure>
    <time_frame>Ongoing</time_frame>
    <description>To estimate the prevalence of pulmonary fibrosis in individuals with rheumatoid arthritis. Subjects will include patients that have rheumatoid arthritis-only.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Natural History</measure>
    <time_frame>Ongoing</time_frame>
    <description>To define the natural history of pulmonary fibrosis associated with rheumatoid arthritis in a prospective, longitudinal study.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">132</enrollment>
  <condition>Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Combo</arm_group_label>
    <description>Patients with rheumatoid arthritis and biopsy-proven pulmonary fibrosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pulmonary fibrosis</arm_group_label>
    <description>Patients with biobsy-proven idiopathic pulmonary fibrosis only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rheumatoid arthritis</arm_group_label>
    <description>Patients with rheumatoid arthritis only.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects will include individuals with (1) rheumatoid arthritis and biopsy-proven pulmonary&#xD;
        fibrosis, (2) rheumatoid arthritis-only, and (3) biopsy-proven idiopathic pulmonary&#xD;
        fibrosis-only.@@@&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Non-smokers (never smoked or no smoking within the previous 2 years) who are 21 years of&#xD;
        age or older with any of the following:&#xD;
&#xD;
        Rheumatoid arthritis with biopsy-proven pulmonary fibrosis or;&#xD;
&#xD;
        Rheumatoid arthritis only, or;&#xD;
&#xD;
        Biopsy-proven idiopathic pulmonary fibrosis.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Forced expiratory volume in one second (FEV1) less than 1L.&#xD;
&#xD;
        Inhalational exposure to fibrogenic fibers or dusts (e.g., asbestos, silica, coal,&#xD;
        beryllium).&#xD;
&#xD;
        Chronic cardiopulmonary disorders other than pulmonary fibrosis.&#xD;
&#xD;
        Other collagen vascular disorders (e.g., systemic lupus erythematosus, scleroderma,&#xD;
        polymyositis, mixed connective tissue disease).&#xD;
&#xD;
        Non-rheumatoid arthritis.&#xD;
&#xD;
        Viral infections associated with pulmonary fibrosis (e.g., hepatitis B, hepatitis C, human&#xD;
        immunodeficiency virus).&#xD;
&#xD;
        Uncorrectable bleeding diathesis.&#xD;
&#xD;
        Pregnancy or lactation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernadette R Gochuico, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Human Genome Research Institute (NHGRI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_1999-HG-0056.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <verification_date>September 2022</verification_date>
  <study_first_submitted>November 3, 1999</study_first_submitted>
  <study_first_submitted_qc>November 3, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 1999</study_first_posted>
  <last_update_submitted>September 27, 2022</last_update_submitted>
  <last_update_submitted_qc>September 27, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Interstitial Lung Disease</keyword>
  <keyword>Collagen Vascular Disease</keyword>
  <keyword>Extracellular Matrix</keyword>
  <keyword>Pulmonary Function</keyword>
  <keyword>DTPA Lung Clearance Scan</keyword>
  <keyword>Natural History</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

